Injectable Cisplatin-Loaded Biodegradable Poly(anhydride-ester) for Treating Head and Neck Cancer: Preclinical Studies

Christine Warwar Damouny; Narmeen Matta; Muhammad Abdel Haq; Abraham Nyska; Peter Siman; Abraham J. Domb

doi:10.1021/acsbiomaterials.5c01699

Injectable Cisplatin-Loaded Biodegradable Poly(anhydride-ester) for Treating Head and Neck Cancer: Preclinical Studies

Christine Warwar Damouny
, Narmeen Matta
, Muhammad Abdel Haq
, Abraham Nyska
, Peter Siman
, Abraham J. Domb^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

Abstract

The first-line treatment for unresectable HPV-negative squamous cell carcinoma of head and neck (SCCHN) patients involves weekly or triweekly systemic cisplatin chemotherapy concurrently with radiotherapy. Cisplatin induces severe systemic toxicity that prevents a portion of patients from receiving the standard of care while redirecting them to less effective alternatives. This means worsening prognosis and overall survival (OS). A single-dose long-acting cisplatin limits toxicity. This is an injectable, biodegradable polyanhydride derived from sebacic acid (SA) and ricinoleic acid (RA) investigated as a targeted small-volume, high-payload carrier to improve safety and enhance efficacy.

Original language	English
Pages (from-to)	1008-1017
Number of pages	10
Journal	ACS Biomaterials Science and Engineering
Volume	12
Issue number	2
DOIs	https://doi.org/10.1021/acsbiomaterials.5c01699
State	Published - 9 Feb 2026

Bibliographical note

Publisher Copyright:
© 2026 American Chemical Society

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

FaDu xenograft
P(SARA)
biodegradable
cisplatin
head and neck cancer
injectable
intratumoral
long-acting
polyanhydride

Access to Document

10.1021/acsbiomaterials.5c01699

Cite this

@article{132a3bb8868d45a29ad19bf96817853c,

title = "Injectable Cisplatin-Loaded Biodegradable Poly(anhydride-ester) for Treating Head and Neck Cancer: Preclinical Studies",

abstract = "The first-line treatment for unresectable HPV-negative squamous cell carcinoma of head and neck (SCCHN) patients involves weekly or triweekly systemic cisplatin chemotherapy concurrently with radiotherapy. Cisplatin induces severe systemic toxicity that prevents a portion of patients from receiving the standard of care while redirecting them to less effective alternatives. This means worsening prognosis and overall survival (OS). A single-dose long-acting cisplatin limits toxicity. This is an injectable, biodegradable polyanhydride derived from sebacic acid (SA) and ricinoleic acid (RA) investigated as a targeted small-volume, high-payload carrier to improve safety and enhance efficacy.",

keywords = "FaDu xenograft, P(SARA), biodegradable, cisplatin, head and neck cancer, injectable, intratumoral, long-acting, polyanhydride",

author = "\{Warwar Damouny\}, Christine and Narmeen Matta and \{Abdel Haq\}, Muhammad and Abraham Nyska and Peter Siman and Domb, \{Abraham J.\}",

note = "Publisher Copyright: {\textcopyright} 2026 American Chemical Society",

year = "2026",

month = feb,

day = "9",

doi = "10.1021/acsbiomaterials.5c01699",

language = "אנגלית",

volume = "12",

pages = "1008--1017",

journal = "ACS Biomaterials Science and Engineering",

issn = "2373-9878",

publisher = "American Chemical Society",

number = "2",

}

TY - JOUR

T1 - Injectable Cisplatin-Loaded Biodegradable Poly(anhydride-ester) for Treating Head and Neck Cancer

T2 - Preclinical Studies

AU - Warwar Damouny, Christine

AU - Matta, Narmeen

AU - Abdel Haq, Muhammad

AU - Nyska, Abraham

AU - Siman, Peter

AU - Domb, Abraham J.

PY - 2026/2/9

Y1 - 2026/2/9

N2 - The first-line treatment for unresectable HPV-negative squamous cell carcinoma of head and neck (SCCHN) patients involves weekly or triweekly systemic cisplatin chemotherapy concurrently with radiotherapy. Cisplatin induces severe systemic toxicity that prevents a portion of patients from receiving the standard of care while redirecting them to less effective alternatives. This means worsening prognosis and overall survival (OS). A single-dose long-acting cisplatin limits toxicity. This is an injectable, biodegradable polyanhydride derived from sebacic acid (SA) and ricinoleic acid (RA) investigated as a targeted small-volume, high-payload carrier to improve safety and enhance efficacy.

AB - The first-line treatment for unresectable HPV-negative squamous cell carcinoma of head and neck (SCCHN) patients involves weekly or triweekly systemic cisplatin chemotherapy concurrently with radiotherapy. Cisplatin induces severe systemic toxicity that prevents a portion of patients from receiving the standard of care while redirecting them to less effective alternatives. This means worsening prognosis and overall survival (OS). A single-dose long-acting cisplatin limits toxicity. This is an injectable, biodegradable polyanhydride derived from sebacic acid (SA) and ricinoleic acid (RA) investigated as a targeted small-volume, high-payload carrier to improve safety and enhance efficacy.

KW - FaDu xenograft

KW - P(SARA)

KW - biodegradable

KW - cisplatin

KW - head and neck cancer

KW - injectable

KW - intratumoral

KW - long-acting

KW - polyanhydride

UR - https://www.scopus.com/pages/publications/105029663696

U2 - 10.1021/acsbiomaterials.5c01699

DO - 10.1021/acsbiomaterials.5c01699

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 41528125

AN - SCOPUS:105029663696

SN - 2373-9878

VL - 12

SP - 1008

EP - 1017

JO - ACS Biomaterials Science and Engineering

JF - ACS Biomaterials Science and Engineering

IS - 2

ER -

Injectable Cisplatin-Loaded Biodegradable Poly(anhydride-ester) for Treating Head and Neck Cancer: Preclinical Studies

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this